GlassScriptPhysician profile
Rae A Winters
NPI 1790268134
$3,255.26
in general payments reported to CMS, 2019-2025
14 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,715 · 2020: $888 · 2022: $61.55 · 2023: $311 · 2024: $103 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,657.57 | 2019-2024 | Wavelight Refractive Suite, Dailies Total1, Precision 7 |
| Coopervision INC. | $941.36 | 2019-2023 | Paragon Crt |
| Johnson & Johnson Surgical Vision, INC. | $136.96 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $125.21 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Bausch & Lomb Americas INC. | $61.04 | 2023-2025 | Vyzulta, Infuse, Alrex |
| Lombart Brothers, INC. | $41.33 | 2023-2024 | Opd-III |
| Rxsight INC | $38.46 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Harrow Eye, LLC | $30.16 | 2025 | Vevye |
| Astellas Pharma US INC | $24.99 | 2023 | Izervay |
| Johnson & Johnson Vision Care, INC. | $22.93 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.32 | 2023 | |
| Abbvie INC. | $14.56 | 2024 | |
| Maculogix, INC. | $14.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rae Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.